INVO Fertility Q1 revenue jumps on clinic growth, acquisition

INVO Fertility

22/06/2026 14:10

Overview
US fertility clinic operator's Q1 revenue rose 23% yr/yr, driven by organic clinic growth and acquisition
Net loss from continuing operations widened to $5.5 mln, impacted by non-cash warrant reclassification
Company eliminated all Series C-2 Preferred Stock and warrant liabilities

Outlook
INVO Fertility says it will focus on organic growth and disciplined fertility clinic acquisitions
Company expects favorable long-term demand trends in fertility care to support growth
Company aims to integrate and grow its current clinic base while expanding its geographic footprint

Result Drivers
ORGANIC CLINIC GROWTH - Co said revenue growth was driven by initiatives at existing clinics, particularly in Georgia
ACQUISITION CONTRIBUTION - Partial-quarter revenue contribution came from the acquisition of Family Beginnings, expanding the clinic network
OPERATIONAL INVESTMENTS - Higher personnel and administrative costs from investments to support expansion weighed on adjusted EBITDA

Company press release: ID:nGNX1NDvJz

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
 
-$5.50 mln
 
Q1 Adjusted EBITDA
 
-$1.26 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for INVO Fertility Inc is $20.00, about 1,233.3% above its June 18 closing price of $1.50

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)